Status:
COMPLETED
Lyrica (Pregabalin) Korean Post Marketing Surveillance Study
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Epilepsy
Neuropathic Pain
Eligibility:
All Genders
Brief Summary
This study collects post-marketing safety and efficacy surveillance data in real world clinical use of pregabalin for its approved indications in Korea.
Detailed Description
continuous patients with target disorders in collaborating institutions
Eligibility Criteria
Inclusion
- Any patient treated with pregabalin for an approved indication by Korean Food and Drug Administration
Exclusion
- Non-consenting
- Hypersensitivity to the active substance or to any of the excipients
- galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
Key Trial Info
Start Date :
July 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
4175 Patients enrolled
Trial Details
Trial ID
NCT01220180
Start Date
July 1 2006
End Date
April 1 2011
Last Update
January 25 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.